What it is
Ipamorelin is a peptide, which means a short chain of amino acids (the building blocks of proteins). It has five amino acids, so it is called a pentapeptide. Two of those amino acids are not found in ordinary proteins: Aib (aminoisobutyric acid) and a naphthalene-containing version of alanine. Two more are 'D' forms, which are mirror images of the usual building blocks. All of this makes it a fully synthetic molecule, built in a laboratory, not a copy of anything the body makes.
More on what it is and where it came from
It belongs to a group of drugs called growth hormone secretagogues. These do not contain growth hormone. Instead they switch on the ghrelin receptor, a docking point in the brain and pituitary gland that the hunger hormone ghrelin normally uses, and the pituitary then releases a burst of the body's own growth hormone.
It was given the research code NNC 26-0161 by Novo Nordisk, and later studied in people by Helsinn. No medicine containing ipamorelin has been approved in the United States or elsewhere. The U.S. Food and Drug Administration (FDA) reviewed it in 2024 and noted that two different chemical forms, the plain peptide (free base) and an acetate salt, are sold under the same name, and that these are different substances.
Ipamorelin was made and described by a research team at the Danish drug company Novo Nordisk, who published it in 1998 under the title 'Ipamorelin, the first selective growth hormone secretagogue'. In the laboratory language of that paper, 'selective' meant one specific thing: in rat pituitary cells and in pigs it released growth hormone about as strongly as the older peptides GHRP-6 and GHRP-2, but unlike them it did not raise the stress hormones ACTH and cortisol, even at amounts more than 200 times higher than the amount needed to release growth hormone. It did not mean selective for muscle, or free of other effects in the body. Novo Nordisk then used ipamorelin as a starting point for a series of smaller, swallowable compounds, and did not develop ipamorelin itself as a medicine. Years later the Swiss company Helsinn ran two mid-stage trials of intravenous ipamorelin for bowel recovery after surgery.
How it is thought to work
Ipamorelin is thought to act on the ghrelin receptor, which sits on cells in the hypothalamus and on the growth-hormone-making cells of the pituitary gland. The FDA described it in 2024 as a ghrelin mimetic that stimulates growth hormone release from the front part of the pituitary without major effects on the stress hormones ACTH and cortisol. Because it works by prompting the pituitary, it depends on the pituitary still working: the FDA noted that people whose pituitary function is completely lost would not be expected to respond.
More on how it works
The same receptor is found outside the brain, in the stomach, intestine, pancreas, heart, lung, kidney, liver and other organs. That is why it was tested for bowel problems. In rats whose bowels had been handled during surgery, intravenous ipamorelin shortened the time to the first bowel movement, and in a separate rat study it sped up stomach emptying and restored the squeezing movement of strips of stomach muscle in an organ bath.
The FDA also pointed out a consequence of this mechanism that is often left out: ghrelin receptors sit in brain regions that handle reward, and in animal studies ghrelin itself changed reward behaviour. The agency wrote that ipamorelin 'could stimulate reward processing and potentially induce reinforcing and addictive behaviors', while adding that no study has shown whether it actually does.
What is established in people
Almost nothing is established in people, and what was tested, failed. There are exactly two human studies of ipamorelin itself. The first, in 1999, gave healthy men a short infusion into a vein and measured how the peptide and growth hormone rose and fell; it tested no benefit. The second, published in 2014, was a mid-stage trial in 114 patients recovering from bowel surgery; ipamorelin did not significantly improve the time to tolerating a meal or any other measure, and the company then stopped developing it. A much larger trial of the same kind, in 320 patients at 45 sites, finished in 2014 and its results were never published. No human trial has tested ipamorelin for muscle growth, fat loss, sleep, anti-ageing, injury recovery or growth hormone deficiency, and the FDA confirmed in 2024 that it could find no human data for any of these, nor any human data at all on the injection-under-the-skin route that products are sold for.
What the studies found
14 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
Trifecta Research Study (NCT07717866)
The only other human record naming ipamorelin.
Full finding, who was studied, and limits
Who: 52 adults with post-traumatic stress disorder, brain injury, depression or thinking difficulties, at a single private site in California. An observational study, not a randomised trial. Sponsor: Axial Therapeutic Research.
The only other human record naming ipamorelin. It is not a study of ipamorelin: the peptide is listed as one ingredient of a bundle called 'Physiological Supplementation', alongside synthetic testosterone, anastrozole, gonadorelin, vitamins, amino acids and fish oil, given in a programme that also included a brain stimulation device and two psychedelic drugs. The study was active and not recruiting as of the record read on 18 November 2026, with no results posted.
Read with care: Nothing about ipamorelin could be learned from this design even when it reports. There is no comparison group, no isolation of any single ingredient, and no randomisation. It is listed here only so that a reader searching trial registries knows what this record is.
- Human trial2014
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
This is the only published human trial of whether ipamorelin does anything.
Full finding, who was studied, and limits
Who: 117 adults in hospital after surgery to remove part of the small or large bowel, at multiple centres. 114 were analysed: 56 received ipamorelin into a vein twice daily and 58 received a dummy infusion, starting the day after surgery and continuing for up to seven days. Neither patients nor staff knew who got which. Registered as NCT00672074, sponsored by Helsinn Therapeutics.
This is the only published human trial of whether ipamorelin does anything. It did not meet its main goal. The middle patient managed a standard solid meal 25.3 hours after the first dose on ipamorelin and 32.6 hours on the dummy infusion, a gap of 7.3 hours that was not statistically significant (p = 0.15). None of the secondary measures showed a difference either: time to first bowel movement (63.0 against 71.6 hours, p = 0.18), a combined measure of upper and lower bowel recovery (63.3 against 75.5 hours, p = 0.29), time to the discharge order being written (79.8 hours in both groups), and length of hospital stay (5 against 6 days, p = 0.29). A later analysis of one subgroup, patients who had open surgery, suggested faster recovery, but that was not the question the trial was designed to answer.
Read with care: The trial was labelled proof-of-concept and the authors themselves said the results should be read with caution, citing the small number of patients and strict entry rules that may have excluded the people most likely to benefit. A result found only in a subgroup after the fact is a hypothesis, not a finding. Reviewing this trial in 2024, the FDA wrote that it 'did not show significant differences between ipamorelin and placebo in the primary and secondary efficacy analyses'.
International Journal of Colorectal Disease · pubmed.ncbi.nlm.nih.gov
- Human trial2014
Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection (NCT01280344)
This was by far the largest human study of ipamorelin ever run, nearly three times the size of the published trial.
Full finding, who was studied, and limits
Who: 320 adults aged 18 to 85 having open removal of part of the small or large bowel, at 45 sites in the United States. Four groups: three different intravenous regimens of ipamorelin and one dummy infusion. Patients, carers, investigators and assessors were all kept unaware of the assignment. Sponsor: Helsinn Therapeutics (U.S.).
This was by far the largest human study of ipamorelin ever run, nearly three times the size of the published trial. It started in April 2011 and finished in May 2014 with the status 'Completed'. No results have ever been posted to the registry and I found no published paper reporting it. The registry record was last updated in April 2017.
Read with care: A completed trial of 320 patients whose results were never made public is a hole in the evidence, not evidence. Because the findings are unknown, nothing can be concluded from it in either direction. Writing in 2024, the FDA said it found only one published clinical study of ipamorelin for bowel recovery after surgery.
- Human trial1999
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
This is the only published study of how ipamorelin behaves in the human body.
Full finding, who was studied, and limits
Who: healthy men (48 enrolled according to the FDA's review; the published report describes eight at each of five dose levels) in a randomised, placebo-controlled dose-escalation study. There were five groups, each with 6 men receiving ipamorelin as a 15-minute infusion into a vein and 2 receiving a dummy infusion.
This is the only published study of how ipamorelin behaves in the human body. Blood levels rose in proportion to the amount given. The peptide was cleared with a final half-life of about two hours. Growth hormone rose to a sharp peak about 40 minutes after the infusion and had fallen to very low levels by six hours at every amount tested. Differences between individuals were larger in the growth hormone response than in the blood levels of the peptide. The authors did not report any side effects linked to the drug.
Read with care: Healthy men only, with a normally working pituitary, and a single short infusion into a vein. It measured a hormone response, not a benefit: it says nothing about whether anything improves. The FDA noted in 2024 that there is no information at all on how the body handles ipamorelin given under the skin, the route sold today, and warned that the pattern seen here does not tell you what would happen with long-term use.
- Review2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Grouped injectable peptides into five classes.
Full finding, who was studied, and limits
Who: A structured search of three medical databases for human and translational studies published between 1 January 2020 and 31 August 2025, by sports medicine researchers at the Steadman Philippon Research Institute in Colorado.
Grouped injectable peptides into five classes. It placed ipamorelin, with CJC-1295 and tesamorelin, in the growth hormone axis group and concluded that these 'remain investigational', with uncertain safety, concerns about product quality, and widespread anti-doping restrictions. Only GLP-1 receptor agonists had reproducible randomised evidence of benefit for a musculoskeletal condition.
Read with care: A narrative review, graded by its own authors as the lowest level of evidence, with recommendations rated mostly 'C'. It does not add new data; it confirms that none exists for ipamorelin in this field.
- Review2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Described ipamorelin's human evidence as consisting of the early study in healthy adults, which showed a clear growth hormone rise peaking roughly 40 to 60 minutes after dosing without disturbing other pituitary or adrenal hormones, and the bowel-surgery trial, which 'did not demonstrate a statistically significant improvement in postoperative gastrointestinal recovery compared with placebo'.
Full finding, who was studied, and limits
Who: Endocrinology researchers at Poznan University of Medical Sciences in Poland reviewed the evidence for peptides sold as 'research compounds' that act on the growth hormone axis, and compared it with the protocols people share online.
Described ipamorelin's human evidence as consisting of the early study in healthy adults, which showed a clear growth hormone rise peaking roughly 40 to 60 minutes after dosing without disturbing other pituitary or adrenal hormones, and the bowel-surgery trial, which 'did not demonstrate a statistically significant improvement in postoperative gastrointestinal recovery compared with placebo'. It reported no trial of ipamorelin for body composition, muscle, fat, sleep or ageing, said that combining it with CJC-1295 is driven largely by anecdote, and stated that controlled evidence for meaningful body-composition outcomes in healthy people remains limited. It described tolerability as generally favourable but stated plainly that there are no long-term safety data.
Read with care: A narrative review, not new research, written by endocrinologists whose stated aim is to help doctors deal with patients who are already self-administering these compounds. It summarises the same two human studies described above.
- Review2024
Evaluation of Ipamorelin-related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List
The most thorough independent assessment that exists.
Full finding, who was studied, and limits
Who: FDA chemists, pharmacologists and physicians reviewed the published chemistry, animal and human data on both chemical forms of ipamorelin, plus the agency's own side-effect report databases, for two proposed uses: growth hormone deficiency and bowel shutdown after surgery.
The most thorough independent assessment that exists. The FDA found no human study at all supporting use for growth hormone deficiency, and only one published clinical study for bowel recovery, which failed. It found no animal studies of acute toxicity, repeat-dose toxicity, genetic damage, reproductive harm or cancer risk. It found no study of the subcutaneous route that products are sold for. It concluded that the criteria 'weigh against' allowing pharmacies to compound either form, and formally proposed not adding them to the list. The document also records that compounded ipamorelin 'has been marketed for use in weight loss management, anti-aging, inflammatory conditions, sleep cycle improvement, and bodybuilding' with no data behind any of it.
Read with care: This is a staff review written to inform an advisory meeting, not a final agency rule. It assessed only the two uses that were nominated. It is a review of other people's work, so its strength depends on the studies available, which were few.
- Animal study2012
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.
Surgery slowed stomach emptying, leaving 78 plus or minus 5 percent of a test meal still in the stomach.
Full finding, who was studied, and limits
Who: Male rats after abdominal surgery with handling of the intestine, plus strips of rat stomach muscle in an organ bath. One author was from Helsinn Healthcare. The abstract does not give group sizes.
Surgery slowed stomach emptying, leaving 78 plus or minus 5 percent of a test meal still in the stomach. Ipamorelin into a vein sped emptying up, leaving 52 plus or minus 11 percent, close to the 44 plus or minus 6 percent in rats that had not had surgery. In the organ bath, ipamorelin restored squeezing movements that surgery had suppressed.
Read with care: Rats and isolated tissue, not people. Measured 15 minutes after a test meal, which is a very short window. Company-linked authorship.
Journal of Experimental Pharmacology · pubmed.ncbi.nlm.nih.gov
- Animal study2009
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.
A single injection into a vein shortened the time to the first bowel movement but did not change the total amount passed, food intake or weight gain over 48 hours.
Full finding, who was studied, and limits
Who: Male rats that had undergone abdominal surgery with handling of the intestine, a standard way of producing the temporary bowel shutdown that can follow surgery. The abstract does not give group sizes.
A single injection into a vein shortened the time to the first bowel movement but did not change the total amount passed, food intake or weight gain over 48 hours. Repeated dosing over two days increased all three.
Read with care: Rats, not people. Work connected to the company that later ran the human trials. A rat model of bowel shutdown is a simplified stand-in for what happens to patients. The human trials that followed did not reproduce the benefit.
Journal of Pharmacology and Experimental Therapeutics · pubmed.ncbi.nlm.nih.gov
- Animal study2001
Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.
Growth hormone secretagogues increased body fat and food intake, and did so even in mice that could not make growth hormone, so the fat gain was not caused by growth hormone.
Full finding, who was studied, and limits
Who: Mice, including mice that cannot make growth hormone, studied at the University of Cambridge.
Growth hormone secretagogues increased body fat and food intake, and did so even in mice that could not make growth hormone, so the fat gain was not caused by growth hormone. Growth hormone itself did not raise the proportion of body fat in normal mice.
Read with care: Mice, not people. It is included here because it points the opposite way to the usual marketing: in this experiment the class of drugs that ipamorelin belongs to made animals fatter, not leaner.
Biochemical and Biophysical Research Communications · pubmed.ncbi.nlm.nih.gov
- Animal study2000
The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.
Both ipamorelin and GHRP-6 increased the total mineral content of bone, measured by a bone-density scan.
Full finding, who was studied, and limits
Who: Adult female rats treated for 12 weeks, by a group at Sahlgrenska University Hospital in Sweden, with collaborators from Novo Nordisk.
Both ipamorelin and GHRP-6 increased the total mineral content of bone, measured by a bone-density scan. The increase came mainly from the bones being bigger, not from the bone itself being denser.
Read with care: Rats, not people. This is the longest animal study found here, and it still only ran 12 weeks. 'More mineral because the bone is larger' is a different thing from stronger bone, and no fracture outcome was measured.
- Animal study1999
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Bone lengthening rose from 42 micrometres a day in untreated rats to 44, 50 and 52 micrometres a day across the three treated groups (p less than 0.0001), and weight gain rose with the amount given.
Full finding, who was studied, and limits
Who: Adult female rats given ipamorelin under the skin at one of three strengths, or nothing, for 15 days.
Bone lengthening rose from 42 micrometres a day in untreated rats to 44, 50 and 52 micrometres a day across the three treated groups (p less than 0.0001), and weight gain rose with the amount given. Blood markers of growth (IGF-I and its binding proteins) and markers of bone turnover did not change. The pituitary's growth hormone response to a test injection was slightly reduced after ipamorelin treatment.
Read with care: Rats, not people, and 15 days is short. Bone lengthening in a rat is not the same as any outcome a person would notice. The blood markers that usually track growth hormone activity did not move, which the authors could not explain. The slight blunting of the pituitary response raises the question of whether the effect lasts.
- Animal study1998
Ipamorelin, the first selective growth hormone secretagogue.
This is the paper that introduced ipamorelin.
Full finding, who was studied, and limits
Who: Rat pituitary cells grown in a dish, anaesthetised rats, and awake female pigs. Done by the Novo Nordisk team that created the compound. The abstract does not give animal numbers.
This is the paper that introduced ipamorelin. In rat pituitary cells it released growth hormone with a potency close to the older peptide GHRP-6, reaching a maximum response of 85 plus or minus 5 percent of what GHRP-6 produced. In pigs it released as much growth hormone as GHRP-6. The reason the authors called it 'selective' was that, unlike GHRP-6 and GHRP-2, it did not raise the stress hormones ACTH or cortisol even at amounts more than 200 times above the amount that released growth hormone.
Read with care: Cells and animals, not people. Written by the company that invented the molecule. 'Selective' here is a narrow laboratory claim about two stress hormones, not a statement that the compound is safe or that it acts only where you want it to.
- Animal study1998
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
Ipamorelin was cleared from the blood about five times more slowly than GHRP-6, and left the body mainly in urine rather than bile.
Full finding, who was studied, and limits
Who: Male rats, comparing ipamorelin with GHRP-2, GHRP-6 and two other new peptides. The abstract does not give animal numbers.
Ipamorelin was cleared from the blood about five times more slowly than GHRP-6, and left the body mainly in urine rather than bile. Between 60 and 80 percent was recovered unchanged, which the authors read as the peptide chain being reasonably resistant to being broken down. When given into the nose, about 20 percent reached the bloodstream, against roughly 50 percent for GHRP-2. Reporting the same work, the FDA noted a half-life in rats of about 27 minutes after an injection into a vein.
Read with care: Rats, not people. Company research. It says nothing about what happens after an injection under the skin, which is the route products are sold for; the FDA stated in 2024 that it could find no study of that route in animals or people.
Safety findings
- In the one published human trial, side effects were common in both groups and most were put down to the surgery. But three of them were more frequent on ipamorelin than on placebo: low blood potassium (12.5 percent against 3.4 percent), sleeplessness (10.7 percent against 5.2 percent), and high blood sugar at discharge (14.3 percent against 8.6 percent). Serious events occurred in 17.9 percent on ipamorelin and 15.5 percent on placebo. Two patients in the ipamorelin group died; both had had bowel surgery for colon cancer and developed a leak at the surgical join, and the causes of death were given as high potassium with blood clots in the aorta, sepsis, a perforated ulcer, and kidney failure with sepsis from pneumonia. Source: fda.gov
- The FDA's own summary of that trial is cautious but pointed: 'Although it is unclear whether the deaths reported in the above study were related to ipamorelin, their occurrence in ipamorelin-treated subjects, along with the higher rates of hypokalemia and hyperglycemia reported in ipamorelin-treated subjects, raises safety concerns about the use of ipamorelin in compounding.' On its public list of bulk substances that may present significant safety risks, the agency states more bluntly that 'a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility'. Source: fda.gov
- The 1999 study in healthy men reported no side effects attributable to the drug, but it was a single short infusion, so it could not detect anything that takes time to appear. Source: pubmed.ncbi.nlm.nih.gov
- The FDA searched its adverse event reporting system up to 30 September 2023 and found two non-serious reports, both involving compounded products in adults. A 32-year-old man using a compounded nasal spray for sinus headache had watering eyes and headache, which were assumed to be a product quality problem; the website that sold it had no working phone number and took payment in a way the FDA described as avoiding detection by authorities. A 46-year-old man injecting a compounded mixture of ipamorelin and sermorelin for two months developed pain in his left elbow joint, which eased but did not resolve after he stopped. Because that product contained two peptides, the FDA said no link to ipamorelin could be assessed. A separate database of food and supplement reports found no cases. Source: fda.gov
5 more safety findings
- There are no long-term human safety data at all. The longest human exposure in a published study was seven days of treatment after surgery. A 2026 review of growth hormone axis peptides states that no long-term safety data exist. Source: pmc.ncbi.nlm.nih.gov
- The animal safety file is close to empty. In 2024 the FDA reported that it could find no published animal studies of acute toxicity, repeat-dose toxicity, genetic damage, developmental or reproductive harm, or cancer risk for either form of ipamorelin. It concluded that 'nonclinical toxicity studies were too limited in scope and duration to inform safety considerations'. Source: fda.gov
- Two concerns the FDA raised that have never been tested. First, reproduction: a mouse study found that switching the ghrelin system either on or off harmed fertilisation, early embryo development and implantation, and the FDA said it remains to be determined whether ipamorelin, which acts on the same receptor, would do the same. Second, reward and dependence: ghrelin receptors sit in brain reward circuits, and the FDA wrote that ipamorelin 'may have behavioral reinforcing properties, which can contribute to development of addiction', while noting that no study has shown whether it does. Source: fda.gov
- A theoretical risk carried over from growth hormone itself. Because ipamorelin raises the body's own growth hormone and therefore IGF-1, the FDA said it was concerned that the risks listed on approved growth hormone labels may apply: increased risk of new growths, glucose intolerance and diabetes, raised pressure inside the skull, fluid retention, underactive adrenal gland and thyroid, a hip problem in children, worsening of existing spinal curvature, and pancreatitis. It added that there are insufficient data to conclude ipamorelin would not raise similar concerns. Source: fda.gov
- Product quality is itself a safety issue here. The FDA judged both forms 'not well-characterized', because data on impurities, clumping of the peptide (aggregates) and bacterial endotoxins were missing from the published literature and from the certificates of analysis submitted. It said it could not rule out the risk that an injected product would provoke an immune response, a risk it considers greater for injection under the skin than into a vein. It also noted that the free base barely dissolves in water, so it is unclear how the injectable product described in the applications could be made at all. Source: fda.gov
Rules and status
Not an FDA-approved drug, and not a component of any approved drug. As of 18 November 2026 it is not on the list of substances that pharmacies may compound from under section 503A, and FDA advisers voted against adding it. Ipamorelin acetate remains in 'Category 2' of the FDA's interim policy for outsourcing facilities under section 503B, the group of substances the agency says may present significant safety risks.
The full history, with dates
Approval: no product containing ipamorelin is approved in the United States, there is no United States Pharmacopeia monograph for either form, and it is not a component of any approved drug. Compounding: two pharmacies, Wells Pharmacy Network and LDT Health Solutions, nominated ipamorelin for the 503A bulk drug substances list, proposing an injection under the skin for growth hormone deficiency. FDA staff reviewed both chemical forms and, in a briefing document dated 19 August 2024, proposed not adding either. At the Pharmacy Compounding Advisory Committee meeting on 29 October 2024 the committee voted 0 in favour, 12 against and 1 abstention on ipamorelin (free base), and 0 in favour, 12 against and 1 abstention on ipamorelin acetate; the minutes record that members 'agreed that there was a lack of information supporting safety and efficacy shown in the available data'. Those nominations were later withdrawn by the nominators, and the FDA's category list dated 14 May 2026 shows ipamorelin in no 503A category at all. Separately, ipamorelin acetate was added on 29 September 2023 to Category 2 under the 503B interim policy for outsourcing facilities, and it is still there on the FDA page current as of 22 April 2026. The FDA's stated reason on that page is that compounded drugs containing it 'may pose risk for immunogenicity for certain routes of administration' because of 'the potential for aggregation or peptide-related impurities'; that it 'also contains unnatural amino acids, which add to the complexity of peptide characterization'; that 'a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility'; and that the FDA 'has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration', so 'the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes'. The same entry is repeated in the table of substances that were nominated but withdrawn. 2026 developments: ipamorelin was NOT on the agenda of the Pharmacy Compounding Advisory Committee meeting held on 23 and 24 July 2026, and no FDA briefing document on ipamorelin was issued in 2025 or 2026; the October 2024 document remains the agency's published assessment. On 30 October 2026 the Department of Health and Human Services published a notice in the Federal Register (91 FR 68526) of a draft, non-binding enforcement discretion policy for compounding certain peptides under section 503A. The notice itself names no peptides; Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Ipamorelin is not among them. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' and gave two weeks for comment. Nothing in any of this amounts to approval.
Source: fda.gov (source dated 2026-04-22)
In sport: Prohibited at all times, in and out of competition. Ipamorelin is named in class S2 (Peptide hormones, growth factors, related substances, and mimetics), section S2.2.4 'Growth hormone releasing factors', in the line 'growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]'. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). The 2026 List states that all substances in S2 are non-Specified Substances. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| It is 'selective', so it gives you growth hormone without any of the other hormonal effects. | 'Selective' comes from the title of the 1998 paper and means one narrow thing: in rat cells and pigs, ipamorelin released growth hormone without raising the stress hormones ACTH and cortisol, unlike the older peptides it was compared with. It was never a claim about the rest of the body. In the one human trial that measured side effects, low blood potassium, sleeplessness and high blood sugar were all more common on ipamorelin than on placebo. Source: pubmed.ncbi.nlm.nih.gov |
| It builds muscle and strips fat. | No human trial has measured muscle or fat with ipamorelin. The FDA reported in 2024 that it found no data at all for these uses. In rats it increased bone lengthening and weight gain; in mice, growth hormone secretagogues increased body fat and food intake, and did so even in mice that could not make growth hormone. A 2026 review found controlled evidence for meaningful body-composition outcomes in healthy people to be limited. Source: fda.gov |
| It improves deep sleep and slows ageing. | No study in people has tested either. The FDA's 2024 review records that compounded ipamorelin 'has been marketed for use in weight loss management, anti-aging, inflammatory conditions, sleep cycle improvement, and bodybuilding', and then states that the only human data it could find were the 1999 study of blood levels and the failed bowel-surgery trial. Sleeplessness, not better sleep, was the side effect reported more often on ipamorelin in that trial. Source: fda.gov |
| It has been through clinical trials, so it is proven. | It went through trials and they did not work out. The published mid-stage trial in 114 bowel-surgery patients missed its main goal and every secondary measure. Quoting a later paper, the FDA records that 'due to these disappointing results, its development was discontinued'. A second, larger trial in 320 patients completed in 2014 and its results were never published. Source: pubmed.ncbi.nlm.nih.gov |
| It is safer than growth hormone because your own body controls the release. | Unknown. The FDA said in 2024 that there are insufficient data to conclude that ipamorelin would not raise the same safety concerns listed on approved growth hormone labels, which include glucose intolerance and diabetes, fluid retention and increased risk of new growths. It also found no animal studies of repeat-dose toxicity, reproductive harm or cancer risk, and no human study longer than a week of dosing. Source: fda.gov |
| The 2026 federal peptide changes made it legal again. | They did not cover it. Ipamorelin was not discussed at the July 2026 advisory committee meeting, and the HHS policy announced on 30 October 2026 names six peptides in its Appendix A (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500); ipamorelin is not one of them. The FDA page current as of 22 April 2026 still shows ipamorelin acetate in Category 2 as a substance that may present significant safety risks. Source: hhs.gov |
| Every batch is the same thing, since it is a simple five-amino-acid peptide. | The FDA found the opposite. Reviewing the two applications, it noted that the certificates of analysis named one form in the title and a different one by molecular weight, that the name, registry number and certificate did not match each other, and that the free base and the acetate salt are different substances sold under the same name. It judged both forms 'not well-characterized' and said testing for impurities, aggregates and bacterial endotoxins was missing. Source: fda.gov |
| It is fine for competitive athletes because it is not a steroid. | It is banned in sport at all times. Growth hormone secretagogues are prohibited under class S2 of the World Anti-Doping Agency's list, and ipamorelin is named as an example. Analytical chemists have published methods for finding it and its breakdown products in athletes' urine, and Danish customs seizures have included modified versions of it. Source: pubmed.ncbi.nlm.nih.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match the expected molecular weight of about 711.9 g/mol for the free base, formula C38H49N9O5. The report should confirm the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, including the amidated C-terminus.
- Confirmation of the unusual building blocks, because they are what makes this molecule hard to characterise. Two residues are not natural amino acids (Aib and 2-naphthylalanine) and two are D-forms (mirror images). The FDA specifically said that less is known about purifying and analysing unnatural amino acids, and that this adds to the difficulty. A report that does not address stereochemistry has not addressed identity.
- Which form was tested, stated plainly: the free base (CAS 170851-70-4) or the acetate salt (the FDA lists CAS 1258196-85-8). For an acetate, the certificate should give acetate content and water content. The FDA found applications where the name, the registry number and the certificate contradicted each other.
- Purity by HPLC with individual impurity limits, not just a single purity percentage. The FDA's complaint about the certificates it saw was precisely this: one of them gave a purity figure with 'no impurity attribute control to demonstrate the impurity profiles', and the best the agency could find elsewhere was a blanket limit with no information on what the impurities were.
- A test for aggregates (peptide molecules clumping together), for example by size exclusion chromatography. The FDA named aggregation as the main reason it could not rule out an immune reaction to injected ipamorelin.
- Bacterial endotoxin and bioburden or sterility results for anything injectable. The FDA stated that endotoxin testing for injectable routes was lacking for both forms of ipamorelin.
- A lot-specific certificate: results tied to the batch number on the vial, naming the testing laboratory and dated.
- Content, meaning how much peptide is actually in the vial, which is a different measurement from purity.
What is not known
- What happened in the 320-patient trial, NCT01280344? It completed in May 2014 and no results were ever posted or published. It is the largest human study of ipamorelin ever conducted and its findings are unknown.
- Does ipamorelin do anything useful in any person, for any condition? The only published trial of a clinical outcome failed, and development stopped.
- What happens when it is injected under the skin, which is how it is sold? The FDA stated in 2024 that it found no human or animal data on that route. Everything known about its behaviour in the body comes from infusions into a vein.
- Is it safe over months or years? No human study dosed for longer than a week, and no animal study of repeat-dose toxicity, genetic damage, reproductive harm or cancer risk has been published.
- Could it affect fertility or pregnancy? A mouse study showed that disturbing the ghrelin system in either direction harmed fertilisation and early embryo development. The FDA said it remains to be determined whether ipamorelin does the same; nobody has tested it.
- Could it be habit-forming? The FDA raised this because ghrelin receptors sit in brain reward circuits, and said no study has established whether ipamorelin has reinforcing properties.
- Why did the rat results not carry over to patients? The rodent bowel studies were clearly positive and the human trials were not. Nobody has published an explanation.
- Who holds the rights to ipamorelin now, and whether anyone intends to develop it. Novo Nordisk created it and moved on to swallowable successors; Helsinn ran the bowel trials and stopped. No current development programme was found.
- The acetate salt's registry number. The FDA lists one number for it while noting that the free base's number is used for the acetate in some public references, and PubChem lists only the free base number. Certificates of analysis should be read with that in mind.
Sources
All 33 sources
- PubChem: Ipamorelin, CID 9831659 (formula, weight, CAS, synonyms, sequence). pubchem.ncbi.nlm.nih.gov
- Raun et al. 1998, the original description: 'Ipamorelin, the first selective growth hormone secretagogue'. pubmed.ncbi.nlm.nih.gov
- Ankersen et al. 1998, peptides derived from ipamorelin aimed at oral activity. pubmed.ncbi.nlm.nih.gov
- Johansen et al. 1998, pharmacokinetics in rats and nasal absorption. pubmed.ncbi.nlm.nih.gov
- Johansen et al. 1999, longitudinal bone growth in rats. pubmed.ncbi.nlm.nih.gov
- Gobburu et al. 1999, pharmacokinetics and pharmacodynamics in 48 healthy men. pubmed.ncbi.nlm.nih.gov
- Svensson et al. 2000, bone mineral content in adult female rats over 12 weeks. pubmed.ncbi.nlm.nih.gov
- Lall et al. 2001, growth-hormone-independent increase in fat in mice. pubmed.ncbi.nlm.nih.gov
- Andersen et al. 2001, ipamorelin against steroid-induced loss of bone formation in rats. pubmed.ncbi.nlm.nih.gov
- Jimenez-Reina et al. 2002, chronic treatment and the pituitary somatotroph population in young female rats. pubmed.ncbi.nlm.nih.gov
- Venkova et al. 2009, rodent model of bowel shutdown after surgery. pubmed.ncbi.nlm.nih.gov
- Greenwood-Van Meerveld et al. 2012, stomach emptying in a rodent model. pubmed.ncbi.nlm.nih.gov
- Beck et al. 2014, phase 2 trial in bowel resection patients. pubmed.ncbi.nlm.nih.gov
- Ferro et al. 2017, structure-activity relationships for peptidic growth hormone secretagogues, including detection in urine. pubmed.ncbi.nlm.nih.gov
- Gajda et al. 2019, modified ipamorelin found in seized doping material. pubmed.ncbi.nlm.nih.gov
- Mohammadi et al. 2020, ghrelin mimetics and pain responses in rats. pubmed.ncbi.nlm.nih.gov
- Sinha et al. 2020, review of growth hormone secretagogues and body composition in men. pubmed.ncbi.nlm.nih.gov
- Mendias and Awan 2026, review of approved and unapproved peptides in sports medicine. pubmed.ncbi.nlm.nih.gov
- Villegas Meza et al. 2026, structured review of injectable peptides in sports medicine. pubmed.ncbi.nlm.nih.gov
- Dominikowski et al. 2026, review of performance-enhancing peptides acting on the growth hormone axis. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT00672074, phase 2 ileus trial, completed, no results posted. clinicaltrials.gov
- ClinicalTrials.gov NCT01280344, phase 2 dose-finding trial in 320 patients, completed 2014, no results posted. clinicaltrials.gov
- ClinicalTrials.gov NCT07717866, observational study using ipamorelin as part of a multi-drug programme. clinicaltrials.gov
- FDA briefing document on ipamorelin-related bulk drug substances, dated 19 August 2024, for the 29 October 2024 advisory committee. fda.gov
- FDA: final summary minutes of the 29 October 2024 Pharmacy Compounding Advisory Committee meeting, with the vote tallies. fda.gov
- FDA: 29 October 2024 advisory committee meeting page. fda.gov
- FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026), with the Category 2 entry for ipamorelin acetate. fda.gov
- FDA: 503A nominated substances by category, updated 14 May 2026 (ipamorelin appears in no category). fda.gov
- FDA: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting page (ipamorelin not on the agenda). fda.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement discretion policy for 503A peptide compounding. govinfo.gov
- WADA 2026 Prohibited List (S2.2.4 names ipamorelin). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.